Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07632664
Recruiting Not applicable

Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients

NCT07632664 · tracked via the Priya Life Science China tracker
Sponsor
Peking University People's Hospital
Phase
Not applicable
Started
2024-08-01
Last updated
2026-07-15

Condition(s) studied

Lung NeoplasmThoracic Surgical ProceduresPerioperative CarePostoperative RehabilitationAged

Investigational drug(s) / intervention(s)

Pulmonary Lobectomy plus Mediastinal Lymph Node SamplingPulmonary Segmentectomy plus Mediastinal Lymph Node SamplingPulmonary Wedge Resection plus Mediastinal Lymph Node Sampling

Pulmonary Lobectomy plus Mediastinal Lymph Node Sampling: Standard anatomical lobectomy combined with systematic mediastinal lymph node sampling for early-stage T1N0M0 non-small cell lung cancer in patients aged ≥65 years; postoperative stratified adaptive perioperative management guided by MRD and tumor biomarkers.

Pulmonary Segmentectomy plus Mediastinal Lymph Node Sampling: Curative segmentectomy with mediastinal lymph node sampling after preoperative comprehensive geriatric risk assessment (CGA, VES-13, ASA grading); postoperative personalized perioperative treatment stratified by postoperative minimal residual disease status.

Pulmonary Wedge Resection plus Mediastinal Lymph Node Sampling: Wedge resection plus mediastinal lymph node sampling for eligible elderly early lung cancer patients; low-risk subjects receive de-escalated adaptive perioperative treatment, while high-risk patients receive intensified comprehensive therapy based on postoperative risk stratification.

Study summary

This multicenter prospective clinical study focuses on elderly patients with lung cancer. The investigators will build a standardized clinical registry database, develop perioperative risk stratification and surgical early-warning models, optimize individualized surgical regimens, construct multidisciplinary perioperative comprehensive therapy, integrated Chinese-Western medicine full-cycle management and personalized postoperative rehabilitation systems, so as to form a whole-process optimized treatment model for elderly lung cancer.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Aged ≥65 years old 2. Pathologically confirmed non-small cell lung cancer with clinical stage eligible for curative surgical resection 3. Complete preoperative geriatric comprehensive assessment data available 4. Capable of finishing planned surgery and long-term follow-up 5. Voluntarily sign informed consent form Exclusion Criteria: 1. History of other malignant tumors within recent 5 years 2. Severe organic dysfunction of heart, liver, renal or respiratory system that cannot tolerate thoracic surgery 3. Preoperative confirmed distant metastasis preventing radical resection 4. Uncontrolled active severe infection or obvious coagulation disorders 5. Severe psychiatric disorder or cognitive dysfunction failing to cooperate with treatment and follow-up 6. Refuse random grouping and postoperative regular monitoring

Primary outcome measure(s)

  • Overall Survival (OS) — Up to 4 years after surgical resection
    The time from randomization to all-cause death, to compare long-term survival difference among lobectomy, segmentectomy and wedge resection groups in elderly early-stage lung cancer patients.

Trial sites (1)

FacilityCityRegionStatus
Peking University People's Hospital Beijing Beijing Municipality Recruiting

More Peking University People's Hospital trials in China

Longitudinal Cohort of Thrombosis and Hemostasis Diseases Recruiting
Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT Recruiting
Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging Recruiting
Critical Illness After Hematopoietic Cell Transplantation Starting soon
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma Recruiting

Other trials for the same condition

Clinical Efficacy of Exoskeleton Robot-Assisted Rehabilitation on Lower Limb Functional Recovery in Elderly Patients With Hip Fracture Enrolling by invitation
The Influence of the Timing of Postoperative Rehabilitation Intervention on the Clinical Efficacy of Unilateral Biportal Endoscopic Spine System in the Treatment of Lumbar Disc Herniation Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) Recruiting
Remimazolam Versus Midazolam for General Anesthesia Induction in Elderly Patients Undergoing Non-Cardiac Surgery Recruiting
Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07632664 on ClinicalTrials.gov ↗ ← All trials in China